FDA issues safety alert about PPIs and C. diff

The FDA announced that proton-pump inhibitors used to treat heartburn and acid reflux can increase the risk of diarrhea associated with Clostridium difficile, and said it was working with drugmakers on label changes for their PPI products. C. diff disease can be difficult to treat and can lead to serious complications; it's been a growing problem in hospitals for the past several years. Release | Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.